Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1‐deficient breast cancer cells to PARP1 inhibition

  title={Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1‐deficient breast cancer cells to PARP1 inhibition},
  author={Haipeng Zhang and Na Yu and Yan Chen and Kaowen Yan and Xiaozhen Wang},
  journal={Journal of Cellular Biochemistry},
  pages={13037 - 13045}
Although some progresses have been made in breast cancer therapy, effective treatment for BRCA1‐deficient breast cancer remains to be a great challenge. It has been demonstrated that the PI3K pathway is inappropriately activated in BRCA1‐deficient breast cancers which can be downregulated by microRNA 451 (miR‐451). In addition, although PARP1 inhibitors showed relatively positive results in both preclinical and clinical studies, additional efforts to decrease drug resistance as well as reduce… 

Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer

The critical role of the PI3K/AKT/mTOR pathway in drug resistance, the development of PI3k/AKt/m TOR inhibitors, and strategies to overcome acquired resistance to standard therapies in breast cancer are summarized.

Nanomedicine-Based Delivery Strategies for Breast Cancer Treatment and Management

Evaluating the state-of-the-art tools and taking the challenges involved into consideration, various aspects of the proposed nano-enabled therapeutic approaches have been discussed in this review.

Research and development of drug delivery systems based on drug transporter and nano-formulation

Self-Assembly of Amphiphilic Compounds as a Versatile Tool for Construction of Nanoscale Drug Carriers

Different combinations of cyclodextrin platform conjugated with polymers is considered as drug delivery systems with synergetic effect that improves solubility, targeting and biocompatibility of formulations.

Pharmacogenetics of drugs in breast cancer and new approaches for improvement of their bioavailability

This document is intended to help clarify the role of Twitter in the operation of this website and its role in the social media landscape.



Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition.

Targeting the Akt/mTOR pathway in Brca1-deficient cancers

The results indicate that activation of Akt is involved in Brca1-deficiency mediated tumorigenesis and that the mTOR pathway can be used as a novel target for treatment of Brca 1-deficient cancers.

New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

The data presented here now suggests that the clinical assessment of PARP inhibitors should be extended beyond those with BRCA mutations to a larger group of patients with PTEN mutant tumours.

Negative Regulation of AKT Activation by BRCA1.

It is reported here that BRCA1 deficiency activates the AKT oncogenic pathway, one of the most common alterations associated with human malignancy.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

It is proposed that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair and exploited in order to kill BRCA2-deficient tumours by PARP inhibition alone.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis, illustrating how different pathways cooperate to repair damage.

MicroRNA miR-451 downregulates the PI3K/AKT pathway through CAB39 in human glioma

It is concluded that miR-451 represses glioma in vitro and in vivo, likely through targeting CAB39 directly and inhibiting the PI3K/AKT pathway indirectly.

RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers

Two subsets of luminal progenitors (RANK+ and RANK−) are identified in histologically normal tissue of BRCA1-mutation carriers and it is shown that RANK+ cells are highly proliferative, have grossly aberrant DNA repair and bear a molecular signature similar to that of basal-like breast cancer.